Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective

Published:2024-05-14 Issue:3 Volume:16 Page:338-347
ISSN:1946-6315
Container-title:Statistics in Biopharmaceutical Research
language:en
Short-container-title:Statistics in Biopharmaceutical Research

Author:

Liu Rong¹,Yuan Ying²^ORCID,Sen Suman³,Marchenko Olga⁴,Jiang Qi⁵,Tian Hong⁶,Li Xiaoyun⁶,Lin Ruitao²,Lu Cindy⁷,Zhou Heng⁸

Affiliation:

1. Regeneron Pharmaceuticals, New York, NY

2. The University of Texas MD Anderson Cancer Center, Houston, TX

3. Novartis Pharmaceuticals Corp, East Hanover, NJ

4. Bayer, Whippany, NJ

5. Seagen Biotechnology Research, Bothell, WA

6. BeiGene, Emeryville, CA

7. AstraZeneca Plc, Wilmington, DE

8. Merck & Co, Rahway, NJ

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/19466315.2024.2332650

Reference55 articles.

1. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

2. Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial

3. Combining Multiple Comparisons and Modeling Techniques in Dose-Response Studies

4. Chu, S. Y. (2022), “Challenges and Opportunities in Dose Optimization for Oncology Drug Development,” in Presented at the 35th New England Statistics Symposium, May 22–25, Connecticut: The University of Connecticut.

5. Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP